Affordable Access

Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma.

Authors
Type
Published Article
Journal
The Lancet
0140-6736
Publisher
Elsevier
Publication Date
Volume
2
Issue
8668
Pages
882–885
Identifiers
PMID: 2571813
Source
Medline

Abstract

32 previously untreated patients with multiple myeloma received vincristine, doxorubicin ('Adriamycin'), and dexamethasone (VAD) as first-line therapy. The overall response rate was 84%, with 28% of all patients entering complete remission. Response was rapid, with near-maximum response occurring after two courses of treatment and rapid improvement in bone-marrow function. Median response duration was 18 months and this seemed to be unaffected by initial prognostic criteria or by degree of remission achieved. The projected median survival was 44 months, with 75% of all patients and 83% of responders being alive at 2 years. Side-effects due to steroids were common, but there was only 1 treatment-related death. The high response rate and lack of toxicity offer an advantage over other forms of initial treatment, although other strategies will be necessary to prolong the duration of response.

There are no comments yet on this publication. Be the first to share your thoughts.

Statistics

Seen <100 times
0 Comments
F